Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment
Completed
- Conditions
- Osteoporosis, Postmenopausal
- Registration Number
- NCT01227369
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment
- Detailed Description
Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 4376
Inclusion Criteria
- Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation
Exclusion Criteria
- Do not understand the contents of the questionnaire
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean of composite satisfaction score (CSS) of OPSAT-QTM 0day
- Secondary Outcome Measures
Name Time Method Mean of subscale satisfaction scores of OPSAT-QTM oday
Trial Locations
- Locations (1)
GSK Investigational Site
🇰🇷Seoul, Korea, Republic of
GSK Investigational Site🇰🇷Seoul, Korea, Republic of